Recruiting EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors NCT07262619 Conditions Advanced Solid Tumors, Endometrial Cancer, Endometrial Neoplasms, +21 more Locations Morristown Medical Center — Morristown, New Jersey, United States Memorial Sloan Kettering Cancer Center (MSKCC) — New York, United States University of Texas MD Anderson Cancer Center — Houston, Texas, United States GenesisCare North Shore (Oncology) — Saint Leonards, New South Wales, Australia View more locations Show fewer locations Loading locations... View Trial Details
Recruiting Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer NCT06250036 Conditions Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer Locations Addenbrooke's Hospital — Cambridge, Cambridgeshire, United Kingdom Royal Devon University Healthcare Foundation Trust — Exeter, Devon, United Kingdom Ninewells hospital and Medical School — Dundee, United Kingdom Kent & Canterbury Hospital — Canterbury, Kent, United Kingdom View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. NCT06116136 Conditions Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, +7 more Locations Ocala Oncology Center Pl — Ocala, Florida, United States Investigative Clinical Research of Indiana, Llc — Noblesville, Indiana, United States MD Anderson Cancer Center — Houston, Texas, United States The Queen Elizabeth Hospital — Woodville South, Australia View all 49 locations View more locations Show fewer locations Loading locations... View Trial Details
